Prophylactic intravenous gentamicin with sedation-free cystoscopic injection of BoNT-A: No demonstrable adverse extravesical neuromuscular effects in a pilot safety study of 220 idiopathic overactive bladder patients
| Autor: | Heather Stewart, Alaa Chamsin, Oladapo Feyisetan, Azizan Samsudin, Ahmad M Omar, Timothy P Napier-Hemy, Michael S Floyd |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
business.industry
Urology Neuromuscular Effects Sedation 030232 urology & nephrology medicine.disease Neuromuscular junction 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Overactive bladder Anesthesia medicine Surgery Gentamicin medicine.symptom business 030217 neurology & neurosurgery medicine.drug Botulinum toxin type |
| Zdroj: | Journal of Clinical Urology. 16:91-95 |
| ISSN: | 2051-4166 2051-4158 |
| DOI: | 10.1177/20514158211016651 |
| Popis: | Objectives: To determine whether administration of single dose prophylactic intravenous gentamicin prior to intravesical injection of botulinum toxin type A (BoNT-A) is associated with adverse extravesical neuromuscular effects in idiopathic overactive bladder syndrome. Patients and methods: A retrospective analysis of 220 consecutive idiopathic overactive bladder patients following sedation-free flexible cystoscopic injection of intravesical BoNT-A. All patients received a single dose of intravenous gentamicin (160 mg) followed by 100-200 IU of BoNT-A. They were followed up at intervals to determine whether they had experienced any adverse extravesical neuromuscular side effects. Results: None of our patients developed adverse extravesical neuromuscular side effects from intravesical botulinum injections with concomitant administration of intravenous gentamicin. Conclusion: Single dose intravenous gentamicin is safe to use as a prophylaxis for intravesical BoNT-A injections of 200 IU or below in idiopathic overactive bladder patients. Level of evidence: Not applicable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|